A Phase III Randomized, Multicenter Non-Inferiority Trial Evaluating the Efficacy of Oral Ibandronate Versus Intravenous Zoledronate in the Reduction of Skeletal-Related Events in Patients With Metastatic Breast Cancer.

Trial Profile

A Phase III Randomized, Multicenter Non-Inferiority Trial Evaluating the Efficacy of Oral Ibandronate Versus Intravenous Zoledronate in the Reduction of Skeletal-Related Events in Patients With Metastatic Breast Cancer.

Withdrawn prior to enrolment
Phase of Trial: Phase III

Latest Information Update: 12 Nov 2013

At a glance

  • Drugs Zoledronic acid (Primary) ; Ibandronic acid
  • Indications Advanced breast cancer; Cancer metastases
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Nov 2007 New trial record.
    • 31 May 2006 Status changed from completed to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top